BioSpace News Archive

Tevogen Bio Holdings Inc. today announced TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy for treatment of COVID-19 in high-risk patients and Long COVID, retains activity against the currently dominant and highly mutated FLiRT strains of SARS-CoV-2 based on a review of this variant’s protein sequences.

Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced participation at the 2024 Truist Securities MedTech Conference, to be held June 17 – 18, 2024, in Boston.

Assertio Holdings, Inc. announced that effective May 31, 2024, the Compensation Committee of the Company’s Board of Directors granted the Company’s new Chief Executive Officer, Brendan P. O’Grady, 500,000 restricted stock units and 1,800,000 stock options.

SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that Eric Schlorff, CEO, will hold a fireside chat at the Virtual Emerging Growth Conference on Wednesday, June 12 at 12:35 p.m. Eastern time (9:35 a.m. Pacific time).

Biomea Fusion, Inc., announced that the Company has received notice from the U.S. Food and Drug Administration that a full clinical hold has been placed on Biomea’s ongoing Phase I/II clinical trials of the Company’s investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes, respectively.

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, FL.

Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets.

Tevogen Bio Holdings Inc., is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders with the aim of addressing the significant unmet needs of large patient populations.

HUTCHMED Limited announces that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in patients with hematological malignancies in China.

EnGeneIC, a clinical-stage biopharmaceutical company pioneering the development of a First-in-Class targeted nanocell for cancer therapy has announced strategic partnerships with Singapore Institute of Advanced Medicine Holdings and Singapore Medical Incorporation.